US OptionsDetailed Quotes
SNPS241220P680000
- 118.40
- 0.000.00%
15min DelayClose Dec 13 15:59 ET
0.00High0.00Low
118.40Open118.40Pre Close0 Volume0 Open Interest680.00Strike Price0.00Turnover0.00%IV-10.49%PremiumDec 20, 2024Expiry Date171.72Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.96Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Synopsys Stock Discussion
Sign in to post a comment
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
1
1
1
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drug...
+2
$Synopsys (SNPS.US)$ wtf, started strong and went down hill
Bitcoin made headlines after breaking $100k, while equities pulled back across the market. By the close, indexes had fallen below their records set Wednesday.
Just past 4:36 pm ET the $S&P 500 Index (.SPX.US)$ fell 19 basis points, the $Dow Jones Industrial Average (.DJI.US)$ fell 0.55%, and the $Nasdaq Composite Index (.IXIC.US)$ fell 0.18%.
MACRO
Continuing jobless claims came in slightly below estimated, at 1.8...
Just past 4:36 pm ET the $S&P 500 Index (.SPX.US)$ fell 19 basis points, the $Dow Jones Industrial Average (.DJI.US)$ fell 0.55%, and the $Nasdaq Composite Index (.IXIC.US)$ fell 0.18%.
MACRO
Continuing jobless claims came in slightly below estimated, at 1.8...
29
11
7
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Good morning, traders. Happy Thursday, December 5th. My name is Kevin Travers, and Bitcoin hit 100k finally while the market is pulling back after Wednesday's top records for the S&P 500, Nasdaq, and Dow Jones. Here are the top news and animal spirits moving stocks:
$Synopsys (SNPS.US)$, a chip-making tool provider fell 11% Thursday after it reported its fourth-quarter earnings Wednesday afternoon. It posted adjusted EPS of $3.40, up 7% c...
$Synopsys (SNPS.US)$, a chip-making tool provider fell 11% Thursday after it reported its fourth-quarter earnings Wednesday afternoon. It posted adjusted EPS of $3.40, up 7% c...
24
4
5
Columns Today's Pre-Market Movers and Top Ratings | Five Below, Dollar General, Southwest Airlines and More
Morning Movers
Gapping up
$Dollar General (DG.US)$ stock rose 1.9% after the discount chain operator reported third-quarter revenue that surpassed expectations, while also trimming the upper end of its annual profit forecast on hurricane-related expenses.
$Southwest Airlines (LUV.US)$ stock rose 2.2% after the carrier revised its fourth-quarter revenue per available seat mile forecast upward, citing ...
Gapping up
$Dollar General (DG.US)$ stock rose 1.9% after the discount chain operator reported third-quarter revenue that surpassed expectations, while also trimming the upper end of its annual profit forecast on hurricane-related expenses.
$Southwest Airlines (LUV.US)$ stock rose 2.2% after the carrier revised its fourth-quarter revenue per available seat mile forecast upward, citing ...
9
1
1
$Synopsys (SNPS.US)$ Results Summary
Record quarterly revenue of $1.636 billion, up approximately 11% year over year (YoY), exceeding the mid-point of guidance.
Quarterly GAAP earnings per diluted share (EPS) of $1.79; non-GAAP EPS of $3.40, up approximately 13% YoY, exceeding guidance.
Achieved record full-year 2024 revenue of $6.127 billion, up approximately 15% YoY, while improving non-GAAP operating margin a...
Record quarterly revenue of $1.636 billion, up approximately 11% year over year (YoY), exceeding the mid-point of guidance.
Quarterly GAAP earnings per diluted share (EPS) of $1.79; non-GAAP EPS of $3.40, up approximately 13% YoY, exceeding guidance.
Achieved record full-year 2024 revenue of $6.127 billion, up approximately 15% YoY, while improving non-GAAP operating margin a...
2
5
$SNPS 241220 700.00C$ lets go
1
$Synopsys (SNPS.US)$
I worked in this company before, it's a good company, I have faith in the management
I worked in this company before, it's a good company, I have faith in the management
2
No comment yet
10xStockPicks OP : This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.